Ozempic and Mounjaro May Affect Memory, but Evidence Is Mixed
A review of research on semaglutide and tirzepatide found that the drugs may affect processes involved in brain function. Human evidence remains mixed: patient-record studies suggest a link to lower dementia risk, while trials found semaglutide did not slow early Alzheimer’s disease.

Researchers from the University of Gothenburg and the University of Copenhagen say Ozempic and Mounjaro may affect brain processes involved in memory and thinking, but evidence that the drugs protect cognition in people remains uncertain. Their review examined semaglutide and tirzepatide, medicines used for obesity and type 2 diabetes.
Animal studies suggest GLP-1 medications can influence learning and memory. Human findings are less consistent, and a link between treatment and lower dementia risk in health-record analyses does not prove the drugs caused that reduction.
More direct trial results also temper expectations. In Novo Nordisk’s EVOKE and EVOKE+ trials, semaglutide did not slow early Alzheimer’s disease, despite changing several biological markers associated with the condition.
The researchers say potential benefits may differ for people whose attention, planning or processing speed is affected by obesity or type 2 diabetes. Those difficulties are often associated with metabolic health and blood vessel function, which may respond differently to treatment than Alzheimer’s disease does.
Improved blood sugar regulation, metabolism or vascular health could potentially help preserve cognitive abilities, the review said. Researchers have not established whether any effect would come from those broader health changes, direct action in the brain, or both.
“We need to find out whether these treatments can help people with obesity or diabetes preserve their cognitive abilities, particularly if treatment begins before cognitive problems become established,” said Stina Börchers, the review’s first author and a researcher affiliated with both universities. “It is also important to identify which patients might benefit.”
The researchers are calling for clinical trials that track memory, attention and other thinking abilities from the start of treatment. Following patients over time could help establish whether the medications protect brain function and which groups, if any, benefit.
They also cautioned that treatment can bring drawbacks for older adults and people who are physically frail. Rapid weight loss can reduce muscle mass, potentially weakening physical function and offsetting some possible benefits.
Christoffer Clemmensen, the review’s senior author and a research group leader at the University of Copenhagen, said advanced obesity medicines could help researchers investigate how metabolism relates to brain function. He said the goal is to distinguish the drugs’ direct and indirect effects and explore treatments designed to preserve cognitive function.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage

- 2DUP Chairman Lord Morrow Loses Wife and Daughter Within Hours in NI

- 3Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds

- 4NASA’s Curiosity Rover Burst Open a Rock and Found Pure Sulfur

- 5Stock Market Today: Dow Futures Slip as Nasdaq Futures Climb Before Earnings

Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists
LifestylePeople Who Don’t Like Celebrating Their Birthday Often Share These 7 Traits















